370 results on '"Portoghese, Philip S."'
Search Results
2. In Memory of Professor Hualiang Jiang
3. Opioid-Induced Tolerance and Dependence in Mice Is Modulated by the Distance between Pharmacophores in a Bivalent Ligand Series
4. A Heterodimer-Selective Agonist Shows in vivo Relevance of G Protein-Coupled Receptor Dimers
5. Opioid receptors in GtoPdb v.2023.1
6. The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids
7. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice
8. A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance
9. Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception
10. Targeting the Brain’s Immune System: A Psychopharmacological Approach to Central Nervous System Infections
11. MMG22 Potently Blocks Hyperalgesia in Cisplatin-Treated Mice
12. N-naphthoyl-ß-naltrexamine (NNTA), a highly selective and potent activator of μ/κ-opioid heteromers
13. Naloxone Acts as a Potent Analgesic in Transgenic Mouse Models of Sickle Cell Anemia
14. Endogenous Opioid Peptides Suppress Cytokine-Mediated Upregulation of HIV-1 Expression in the Chronically Infected Promonocyte Clone U1
15. Opioid receptors in GtoPdb v.2021.3
16. Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model
17. Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands
18. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores
19. Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats
20. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series
21. Specific cross-linking of Lys233 and Cys235 in the mu opioid receptor by a reporter affinity label
22. Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys
23. GRAS flavoring substances 21: the 21st publication by the Expert Panel of the Flavor and Extract Manufacturers Association on recent progress in the consideration of flavoring ingredients generally recognized as safe under the Food Additives Amendment
24. Stereochemical requirements for receptor recognition of the μ-opioid peptide endomorphin-1: Biological activity, NMR and conformational analysis of D-amino acid substituted analogs
25. The δ2-opioid receptor antagonist naltriben reduces motivated responding for ethanol
26. FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR–DOR Heteromer
27. Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5
28. The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward
29. Criteria for the safety evaluation of flavoring substances: The Expert Panel of the Flavor and Extract Manufacturers Association
30. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models
31. Identification of Helical Packing Motifs Common to Bacteriorhodopsin and G Protein-Coupled Receptors
32. Boron tribromide-catalyzed rearrangement of 7,7-diphenylhydromorphone to 6,7-diphenylmorphine: a novel conversion of ketones to allylic alcohols
33. The FEMA GRAS assessment of cinnamyl derivatives used as flavor ingredients
34. Chloroxymorphamine, an Opioid Receptor Site-Directed Alkylating Agent Having Narcotic Agonist Activity
35. Effect of opioid receptor ligands on the μ-S196A knock-in and μ knockout mouse vas deferens
36. Identity of the putative δ1-opioid receptor as a δ–κ heteromer in the mouse spinal cord
37. Medicinal chemistry as we start the next millennium
38. Morphine Tolerance in Mice Changes Response of Heroin from μ to δ Opioid Receptors (44520)
39. Endogenous Opioid Peptides Suppress Cytokine-Mediated Upregulation of HIV-1 Expression in the Chronically Infected Promonocyte Clone U1
40. Opioid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
41. Stereochemistry and innate immune recognition: (+)‐norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll‐like receptor 4 signaling
42. FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR–DOR Heteromer
43. Opiate dienes as dienophiles in the Diels-Alder reaction with 1-cyano-o-quinodimethane
44. Combined Glia Inhibition and Opioid Receptor Agonism Afford Highly Potent Analgesics without Tolerance
45. Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease
46. Monophenylation of morphinan-6-ones with diphenyliodonium iodide
47. Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical μ-opoid receptor
48. Heteromer Induction: An Approach to Unique Pharmacology?
49. Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling.
50. Combined Glia Inhibition and Opioid Receptor Agonism Afford Highly Potent Analgesics without Tolerance.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.